ABSTRACT
While there are numerous potential direct and indirect extensions to this line of research, this section will mention three of them. The first is to consider the drug utilization decision from the point-of-view of physicians. The second is to contemplate the impact of copayments and other factors, particularly health status, on switching from one statin to another. The last is to reflect on the possibility of maximizing the power of claims data in a panel data framework to eliminate the variation that exists due to unobservable variables.
